How to take Talazoparib

Talazoparib (Talazoparib) is a capsule formulation. The recommended dose for the treatment of BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer is 1 mg orally once daily; for the treatment of H The recommended dose for RR-mutated metastatic castration-resistant prostate cancer (mCRPC) is 0.5 mg orally once daily, or 160 mg orally once daily in combination with enzalutamide, until disease progression or unacceptable toxicity.

Patients receiving talazopanib and enzalutamide should also receive concomitantGnRH analog therapy or should undergo bilateral orchiectomy. To control adverse reactions, consider interrupting treatment with or without dose reduction based on severity and clinical manifestations. If more than three dose reductions are required, talazopanib therapy should be discontinued. For patients with breast cancer, the first dose of talazopanib can be reduced to 0.75 mg once daily, the second dose to 0.5 mg once daily, and the third dose to 0.25 mg once daily. For patients with prostate cancer, the first dose of talazopanib can be reduced to 0.35 mg once daily, the second dose to 0.25 mg once daily, and the third dose to 0.1 mg once daily.

The original drug of talazopanib has not yet been marketed in China, so it has not been included in medical insurance. The original drug specification of talazopanib listed overseas is 0.25mg*30 capsules, and the price per box may be around RMB 10,000 (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheaper generics of talazopanib overseas. For example, the price of a box of 1mg*30 pills produced by a Laos pharmaceutical factory may be more than 3,000 yuan (the price may fluctuate due to the exchange rate).